

New Options for Patients with T- Cell Lymphoma

Several Novel Clinical Trial Treatment Options for Patients with Newly Diagnosed or Relapsed/Refractory T- Cell Lymphoma

Eligibility Criteria in General:

- **General criteria for newly diagnosed or relapsed/refractory patients**
 - No active hepatitis or HIV
 - No impaired cardiac function
 - At least 18 years old
 - Adequate laboratory values:
Absolute neutrophil count (ANC) \geq 1k/mm³, Platelets \geq 75 k/mm³, Bilirubin \leq 1.5 times the upper limit of normal (ULN), Alanine transaminase (ALT) \leq 2.5 times the (ULN) or aspartate transaminase (AST) \leq 2.5 times the ULN, Serum creatinine \leq 1.5 times the (ULN)
 - No CNS lymphoma
- **Specifically for Newly Diagnosed/Untreated Patients**
 - Bi-dimensionally measureable nodal disease (cutaneous only disease not eligible) with one of the following diagnosis:
 - Peripheral T-cell lymphoma (unspecified)
 - CD 30+ Anaplastic large cell lymphoma (ALK-1 positive and ALK-1 negative)
 - Angioimmunoblastic T-cell lymphoma
 - Intestinal T-cell lymphoma
 - Subcutaneous panniculitic T-cell lymphoma
- **Specifically for Relapsed/Refractory Patients**
 - Relapsed/Refractory T-cell lymphoma after standard treatments and with bi-dimensionally nodal disease (cutaneous only disease not eligible)
 - No treatment within 2 weeks



Procedure:

- Depending on the trial, procedures will differ
- In general, patients are treated and monitored on a weekly basis which in some cases monitoring can be done by referring physicians

Benefit for Patients:

- May help to improve disease remission rates
- May help to improve progression free and overall survival.

Principal Investigator: Anas Younes, MD

**Protocol # 2008-0484, clinicaltrials.gov
ID (NCT00787527)**

A Phase I/II of Vorinostat plus CHOP in untreated T-cell non-Hodgkin's Lymphoma

**Protocol # 2010-0261, clinicaltrials.gov
ID (NCT01258998)**

A Phase II Study of MK-2206 in Patients with Relapsed Lymphoma

**Protocol # 2008-0805, clinicaltrials.gov
ID (NCT00967044)**

A Phase I/II of Panobinostat (LBH589) plus Everolimus (RAD001) in Patients with Relapsed and Refractory Lymphoma

Schedule an appointment or make referral online at <https://my.mdanderson.org> or call 713-745-5640

For more information about the study, contact Anas Younes, MD, Lymphoma, at 713-792-2860, or ayounes@mdanderson.org or Research Advanced Practice Nurse, Amy Copeland, RN, MSN, at (713)792-9455, or arcopeland@mdanderson.org

For information on related articles or references for this study, visit <http://physicianrelations.org> or <http://clinicaltrials.gov/>